The North Central Cancer Treatment Group (NCCTG) is a multidisciplinary clinical trials organization which is comprised primarily of community clinics. The NCCTG is affiliated with the NCI-designated Mayo Clinic Cancer Center as its research base. The primary cancer treatment objective of the NCCTG is to improve survival and quality of life for patients with malignant disease by conducting high quality cancer treatment research studies based upon sound scientific hypotheses. Our organization is devoted to the care of cancer patients, and is based on the premises that quality cancer treatment research can be conducted by the community clinic, and that the community clinic provides the ultimate proving ground for applicability of new cancer treatment procedures to the general population.
Our specific aims during the next grant period are to: (1) provide an infrastructure to facilitate high quality translational research in collaborative with laboratory scientists at the Mayo Cancer Center and other research organizations: (2) provide cancer patients access to the highest quality of oncologic care in a research setting in or near their home community; (3) facilitate communication between the community clinics, research base, other cooperative groups and the National Cancer Institute with respect to clinical cancer research. (4) provide underserved populations access to NCCTG clinical research protocols. We intend to achieve these goals through close coordination of the NCCTG research agenda with that of the Mayo Clinic Cancer Center to take advantage of the considerable strengths of these two distinct research programs in order to achieve common objective in an efficient and cost- effective manner.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA025224-19S1
Application #
2848714
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1982-01-01
Project End
2000-12-31
Budget Start
1998-02-17
Budget End
1998-12-31
Support Year
19
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Chumsri, Saranya; Sperinde, Jeff; Liu, Heshan et al. (2018) High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance). Clin Cancer Res 24:3053-3058
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
McCleary, Nadine J; Hubbard, Joleen; Mahoney, Michelle R et al. (2018) Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol 9:24-31
Feliciano, Josephine L; Le-Rademacher, Jennifer G; Gajra, Ajeet et al. (2018) Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622). J Geriatr Oncol 9:501-506
Schiff, David; Jaeckle, Kurt A; Anderson, S Keith et al. (2018) Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572. Cancer 124:1455-1463
McWilliams, Robert R; Allred, Jacob B; Slostad, Jessica A et al. (2018) NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab?±?everolimus for metastatic melanoma. Cancer 124:537-545
Sinicrope, Frank A; Shi, Qian; Allegra, Carmen J et al. (2017) Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Oncol 3:472-480
Schild, Steven E; Hillman, Shauna L; Tan, Angelina D et al. (2017) Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol 12:697-703
Reinholz, Monica M; Chen, Beiyun; Dueck, Amylou C et al. (2017) IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831. Clin Cancer Res 23:4203-4211
Bhatia, Aarti K; Lee, Ju-Whei; Pinto, Harlan A et al. (2017) Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 123:4653-4662

Showing the most recent 10 out of 718 publications